Q-omics provides the consensus-scored ZNF565 profile across patient tissues and cancer cell-line models. ZNF565 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF565 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ZNF565 RNA expression shows 21,221 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where ZNF565 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF565 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF565 survival associations across molecular data types. ZNF565 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF565 RNA expression–survival associations across cancer types. High ZNF565 expression shows unfavorable associations in UVM, MESO, LGG and ACC, but favorable associations in UCS and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF565 RNA expression.
This table summarizes ZNF565 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF565. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF565 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LIHC, KIRC and LUAD. The THCA box plot shows higher ZNF565 RNA expression in normal versus tumor tissue (log2 FC = −0.634, t-test p < 0.001).
This table shows molecular features associated with ZNF565 in patient tissues and cancer cell lines. In patient samples, ZNF565 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF565 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
